Loading…
Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): Insights From the Department of Veterans Affairs
Virani, Salim S., Akeroyd, Julia M., Nambi, Vijay, Heidenreich, Paul A., Morris, Pamela B., Nasir, Khurram, Michos, Erin D., Bittner, Vera A., Petersen, Laura A., Ballantyne, Christie M.
Published in Circulation (New York, N.Y.) (20.06.2017)
Published in Circulation (New York, N.Y.) (20.06.2017)
Get full text
Journal Article
Loading…
Proprotein convertase subtilisin–kexin type 9 is elevated in proteinuric subjects: Relationship with lipoprotein response to antiproteinuric treatment
Kwakernaak, Arjan J., Lambert, Gilles, Slagman, Maartje C.J., Waanders, Femke, Laverman, Gozewijn D., Petrides, Francine, Dikkeschei, Bert D., Navis, Gerjan, Dullaart, Robin P.F.
Published in Atherosclerosis (01.02.2013)
Published in Atherosclerosis (01.02.2013)
Get full text
Journal Article
Loading…
Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging Study in Statin-Treated Subjects With Hypercholesterolemia
Ballantyne, Christie M., Neutel, Joel, Cropp, Anne, Duggan, William, Wang, Ellen Q., Plowchalk, David, Sweeney, Kevin, Kaila, Nitin, Vincent, John, Bays, Harold
Published in The American journal of cardiology (01.05.2015)
Published in The American journal of cardiology (01.05.2015)
Get full text
Journal Article
Loading…
Loading…
AMG145, a Monoclonal Antibody Against Proprotein Convertase Subtilisin Kexin Type 9, Significantly Reduces Lipoprotein(a) in Hypercholesterolemic Patients Receiving Statin Therapy: An Analysis From the LDL-C Assessment With Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined With Statin Therapy (LAPLACE)–Thrombolysis in Myocardial Infarction (TIMI) 57 Trial
Desai, Nihar R., Kohli, Payal, Giugliano, Robert P., O’Donoghue, Michelle L., Somaratne, Ransi, Zhou, Jing, Hoffman, Elaine B., Huang, Fannie, Rogers, William J., Wasserman, Scott M., Scott, Robert, Sabatine, Marc S.
Published in Circulation (New York, N.Y.) (27.08.2013)
Published in Circulation (New York, N.Y.) (27.08.2013)
Get full text
Journal Article
Loading…
Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor–independent pathways
Cameron, Jamie, Bogsrud, Martin P., Tveten, Kristian, StrØm, Thea Bismo, Holven, Kirsten, Berge, Knut Erik, Leren, Trond P.
Published in Translational research : the journal of laboratory and clinical medicine (01.08.2012)
Published in Translational research : the journal of laboratory and clinical medicine (01.08.2012)
Get full text
Journal Article
Loading…
Semysinthetic biflavonoid Morelloflavone-7,4′,7″,3‴,4‴-penta-O-butanoyl is a more potent inhibitor of Proprotein Convertases Subtilisin/Kexin PC1/3 than Kex2 and Furin
de Souza, Aline Aparecida, de Andrade, Débora Martins, Siqueira, Fábio da Silva, Di Iorio, Juliana Fortes, Veloso, Marcia Paranho, Coelho, Camila de Morais, Viegas Junior, Claudio, Gontijo, Vanessa Silva, dos Santos, Marcelo Henrique, Meneghetti, Maria Cecília Zorél, Nader, Helena Bonciani, Tersariol, Ivarne Luis dos Santos, Juliano, Luiz, Juliano, Maria Aparecida, Judice, Wagner Alves de Souza
Published in Biochimica et biophysica acta. General subjects (01.12.2021)
Published in Biochimica et biophysica acta. General subjects (01.12.2021)
Get full text
Journal Article
Loading…
Inter-relationships between proprotein convertase subtilisin/kexin type 9, apolipoprotein C-III and plasma apolipoprotein B-48 transport in obese subjects: a stable isotope study in the postprandial state
Chan, Dick C., Wong, Annette T. Y., Pang, Jing, Barrett, P. Hugh R., Watts, Gerald F.
Published in Clinical science (1979) (01.03.2015)
Published in Clinical science (1979) (01.03.2015)
Get full text
Journal Article
Loading…
Loading…
Heparin Does Not Regulate Circulating Human PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) in a General Population—Brief Report
Xia, Vivian Q., Ong, Chui Mei, Zier, Lucas S., MacGregor, John S., Wu, Alan H.B., Chorba, John S.
Published in Arteriosclerosis, thrombosis, and vascular biology (01.02.2023)
Published in Arteriosclerosis, thrombosis, and vascular biology (01.02.2023)
Get full text
Journal Article
Loading…
Lipoprotein apheresis reduces major adverse cardiovascular event incidence in high-lipoprotein (a) subjects on proprotein convertase subtilisin/kexin type 9 inhibitor therapy
Sbrana, Francesco, Bigazzi, Federico, Corciulo, Carmen, Dal Pino, Beatrice
Published in European journal of preventive cardiology (03.06.2024)
Published in European journal of preventive cardiology (03.06.2024)
Get more information
Journal Article
Loading…
Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
Fitzgerald, Kevin, Frank-Kamenetsky, Maria, Shulga-Morskaya, Svetlana, Liebow, Abigail, Bettencourt, Brian R, Sutherland, Jessica E, Hutabarat, Renta M, Clausen, Valerie A, Karsten, Verena, Cehelsky, Jeffrey, Nochur, Saraswathy V, Kotelianski, Victor, Horton, Jay, Mant, Timothy, Chiesa, Joseph, Ritter, James, Munisamy, Malathy, Vaishnaw, Akshay K, Gollob, Jared A, Simon, Amy
Published in The Lancet (British edition) (04.01.2014)
Published in The Lancet (British edition) (04.01.2014)
Get full text
Journal Article
Loading…
Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics
Watts, Gerald F, Chan, Dick C, Somaratne, Ransi, Wasserman, Scott M, Scott, Rob, Marcovina, Santica M, Barrett, P Hugh R
Published in European heart journal (14.07.2018)
Published in European heart journal (14.07.2018)
Get full text
Journal Article
Loading…
Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels - experimental and clinical approaches with lipid-lowering agents
Macchi, C, Banach, M, Corsini, A, Sirtori, C R, Ferri, N, Ruscica, M
Published in European journal of preventive cardiology (01.06.2019)
Published in European journal of preventive cardiology (01.06.2019)
Get more information
Journal Article
Loading…
Association of circulating proprotein convertase subtilisin/kexin type 9 levels and the risk of incident type 2 diabetes in subjects with prediabetes: a population-based cohort study
Shi, Jie, Zhang, Weiwei, Niu, Yixin, Lin, Ning, Li, Xiaoyong, Zhang, Hongmei, Hu, Renming, Ning, Guang, Fan, Jiangao, Qin, Li, Su, Qing, Yang, Zhen
Published in Cardiovascular diabetology (10.12.2020)
Published in Cardiovascular diabetology (10.12.2020)
Get full text
Journal Article
Loading…
Antisense‐mediated reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9): a first‐in‐human randomized, placebo‐controlled trial
Poelgeest, Eveline P., Hodges, Michael R., Moerland, Matthijs, Tessier, Yann, Levin, Arthur A., Persson, Robert, Lindholm, Marie W., Dumong Erichsen, Kamille, Ørum, Henrik, Cohen, Adam F., Burggraaf, Jacobus
Published in British journal of clinical pharmacology (01.12.2015)
Published in British journal of clinical pharmacology (01.12.2015)
Get full text
Journal Article
Loading…
Proprotein convertase Subtilisin/Kexin type 9 (PCSK9) gene polymorphism in hypercholesterolemic Nepalese subjects
Marasini, Surendra, Lamsal, Madhab, Das, Binod Kumar Lal, Chaudhari, Rajendra Kumar, Baral, Nirmal, Jha, Punam, Bhattarai, Narayan Raj, Rai, Keshav, Karki, Prahlad
Published in IHJ Cardiovascular Reports (01.04.2025)
Published in IHJ Cardiovascular Reports (01.04.2025)
Get full text
Journal Article
Loading…
Real-World Analyses of the Treatment Conditions in Patients Initiating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor in Taiwan
Lin, Po-Lin, Wu, Yen-Wen, Lin, Chao-Feng, Yeh, Hung-I, Chang, Wei-Ting, Charng, Min-Ji, Huang, Po-Hsun, Lin, Chih-Chan, Lin, Tsung-Hsien, Lin, Wei-Wen, Hsieh, I-Chang, Kuo, Feng-Yu, Chen, Ching-Pei, Li, Yi-Heng
Published in Journal of Atherosclerosis and Thrombosis (01.09.2023)
Published in Journal of Atherosclerosis and Thrombosis (01.09.2023)
Get full text
Journal Article
Loading…
Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis
Giugliano, Robert P., Pedersen, Terje R., Saver, Jeffrey L., Sever, Peter S., Keech, Anthony C., Bohula, Erin A., Murphy, Sabina A., Wasserman, Scott M., Honarpour, Narimon, Wang, Huei, Lira Pineda, Armando, Sabatine, Marc S.
Published in Stroke (1970) (01.05.2020)
Published in Stroke (1970) (01.05.2020)
Get full text
Journal Article
Loading…